Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MNPR

Monopar Therapeutics Inc

Feb 21 • 04:00PM ET

40.25

Dollar change -0.72
Percentage change -1.76	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE MCRB AFMD ADAP EYPT ADVM CYCN CTMX XBIT GLYC

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.98	Insider Own	35.33%	Shs Outstand	6.10M	Perf Week	-9.91%
Market Cap	245.63M	Forward P/E	-	EPS next Y	-2.38	Insider Trans	0.07%	Shs Float	3.95M	Perf Month	19.54%
Income	-6.47M	PEG	-	EPS next Q	-0.34	Inst Own	42.25%	Short Float	0.78%	Perf Quarter	118.16%
Sales	0.00M	P/S	-	EPS this Y	57.77%	Inst Trans	2.75%	Short Ratio	0.41	Perf Half Y	1522.98%
Book/sh	1.40	P/B	28.68	EPS next Y	-85.09%	ROA	-88.32%	Short Interest	0.03M	Perf Year	1103.29%
Cash/sh	0.99	P/C	40.80	EPS next 5Y	21.48%	ROE	-112.04%	52W Range	1.72 - 54.30	Perf YTD	82.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-14.80%	ROI	-130.89%	52W High	-25.87%	Beta	1.15
Dividend TTM	-	Quick Ratio	5.41	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2241.48%	ATR (14)	5.03
Dividend Ex-Date	-	Current Ratio	5.41	EPS Y/Y TTM	44.30%	Oper. Margin	-	RSI (14)	49.34	Volatility	11.72% 15.29%
Employees	10	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	55.20
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	46.45%	Payout	-	Rel Volume	0.61	Prev Close	40.97
Sales Surprise	-	EPS Surprise	62.81%	Sales Q/Q	-	Earnings	Nov 08 BMO	Avg Volume	75.33K	Price	40.25
SMA20	-9.47%	SMA50	20.37%	SMA200	198.07%	Trades		Volume	45,887	Change	-1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Initiated	Piper Sandler	Overweight	$72
Oct-11-24	Initiated	Rodman & Renshaw	Buy	$50
Jan-28-21	Initiated	ROTH Capital	Buy	$49

Feb-03-25 07:22PM	Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 (Insider Monkey) +10.22%
Jan-23-25 01:10PM	Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics (PR Newswire) +16.78%
07:06AM	Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright (TipRanks)
Dec-31-24 02:36AM	These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year Heres What Analysts Expect in 2025 (TipRanks) -7.76%
Dec-20-24 09:00AM	Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire) +8.53%
04:21PM	Loading…
Dec-05-24 04:21PM	Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu (GlobeNewswire) -14.84%
Dec-03-24 08:00AM	Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +5.27%
Nov-08-24 08:00AM	Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments (GlobeNewswire) +7.31%
Oct-30-24 01:42PM	Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) -9.50%
Oct-28-24 09:15PM	Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) +5.32% -9.09%
04:00PM	Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-25-24 07:31AM	Monopar Therapeutics Secures License for Wilson Disease Treatment (TipRanks) -48.16%
Oct-24-24 07:00AM	Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate (GlobeNewswire) +605.40%
Oct-22-24 08:00AM	Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 (GlobeNewswire)
Oct-16-24 08:28AM	Monopar Therapeutics Expands Portfolio with New Patent Filing (TipRanks)
08:00AM	Loading…
Oct-15-24 08:00AM	Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers (GlobeNewswire)
Oct-08-24 08:30AM	Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial (TipRanks) +5.12%
Oct-07-24 08:00AM	Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers (GlobeNewswire) +10.20%
Sep-12-24 08:00AM	Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr (GlobeNewswire) +64.58%
Sep-04-24 08:00AM	Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-27-24 04:05PM	Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -8.40% -5.83%
Aug-21-24 08:00AM	Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers (GlobeNewswire)
Aug-14-24 08:00AM	Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr (GlobeNewswire) -5.79%
Aug-12-24 12:24PM	Upcoming Stock Splits This Week (August 12 to August 16) Stay Invested (TipRanks) +6.56%
Aug-09-24 02:53PM	MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -19.64%
08:00AM	Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments (GlobeNewswire)
08:00AM	Monopar Therapeutics Announces 1-for-5 Reverse Stock Split (GlobeNewswire)
Jul-09-24 07:00AM	Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr (GlobeNewswire)
Jun-25-24 08:00AM	Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24 (GlobeNewswire)
Jun-11-24 07:30AM	Monopar and NorthStar Amend & Extend Collaboration (GlobeNewswire) +5.22%
08:00AM	Loading…
Jun-10-24 08:00AM	Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting (GlobeNewswire)
Jun-05-24 06:15AM	Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely (InvestorPlace)
May-24-24 08:00AM	Monopar Announces CFO Succession (GlobeNewswire)
May-17-24 09:55AM	Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now (Zacks)
May-09-24 01:55PM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19%
07:00AM	Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline (GlobeNewswire)
Apr-18-24 08:00AM	Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 08:00AM	Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings (GlobeNewswire)
Apr-10-24 08:00AM	Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients (GlobeNewswire) +8.36%
Apr-04-24 09:55AM	Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-03-24 12:00PM	All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy (Zacks)
Mar-28-24 11:53AM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.60%
07:00AM	Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments (GlobeNewswire)
Mar-05-24 07:00AM	Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program (GlobeNewswire) +7.06%
Feb-27-24 07:00AM	Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial (GlobeNewswire) -10.37%
Feb-23-24 11:55AM	5 Best Rising Penny Stocks To Buy (Insider Monkey) +16.07%
Feb-22-24 07:00AM	Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers (GlobeNewswire) +96.49%
Feb-20-24 08:00AM	Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers (GlobeNewswire) +95.27%
Nov-09-23 08:37AM	Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs (GuruFocus.com)
07:00AM	Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Nov-01-23 07:00AM	Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire) +27.91%
Oct-10-23 07:00AM	Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -5.96%
Sep-05-23 07:00AM	Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 07:00AM	Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Aug-08-23 07:00AM	Monopar Provides Encouraging Camsirubicin Clinical Data Update (GlobeNewswire) +15.22%
Jul-11-23 07:00AM	Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore (GlobeNewswire)
Jun-21-23 07:00AM	Monopar to Participate in the Radiopharma Forum by the Lake 2023 (GlobeNewswire)
Jun-14-23 07:00AM	Monopar to Participate in the Maxim Groups Healthcare Virtual Conference (GlobeNewswire)
Jun-01-23 07:00AM	Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update (GlobeNewswire) +7.36%
May-29-23 09:55AM	Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-11-23 07:00AM	Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments (GlobeNewswire) -6.58%
Apr-19-23 09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-28-23 01:40PM	Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication (Benzinga) -51.34%
07:00AM	Monopar to Present at the Jefferies Radiopharma Innovation Summit (GlobeNewswire)
Mar-27-23 05:00PM	Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis (GlobeNewswire)
Mar-23-23 07:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments (GlobeNewswire)
Mar-07-23 07:00AM	Monopar to Present at the 35th Annual Roth Conference (GlobeNewswire)
Feb-27-23 07:00AM	Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials (GlobeNewswire)
Feb-14-23 12:46PM	What's Going On With Monopar Therapeutics Shares Today? (Benzinga)
07:00AM	Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin (GlobeNewswire)
Feb-05-23 08:38AM	We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate (Simply Wall St.)
Jan-26-23 07:00AM	Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT (GlobeNewswire)
Jan-18-23 07:00AM	Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 (GlobeNewswire)
Dec-12-22 07:00AM	Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration (GlobeNewswire) -18.97%
Nov-18-22 01:10PM	Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data (Zacks) -6.42%
09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-16-22 10:09AM	Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Study (Benzinga)
07:00AM	Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial (GlobeNewswire)
Nov-10-22 08:00AM	Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) -24.83%
Oct-27-22 08:00AM	Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 (GlobeNewswire)
Oct-19-22 08:00AM	Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting (GlobeNewswire)
Oct-12-22 08:00AM	Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire)
Oct-05-22 08:50AM	Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients (MarketWatch)
08:00AM	Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis (GlobeNewswire)
Sep-28-22 08:00AM	Monopar to Present at Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire)
Aug-28-22 10:49AM	Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation (Simply Wall St.)
Aug-18-22 09:55AM	Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-11-22 08:05AM	Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire)
May-12-22 08:00AM	Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) -7.96%
Mar-24-22 08:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments (GlobeNewswire)
Mar-21-22 03:18PM	Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-08-22 08:00AM	Monopar to Present at the 34th Annual Roth Conference and Maxims 2022 Virtual Growth Conference (GlobeNewswire) -5.98%
Feb-15-22 08:05AM	Monopar Announces Clinical and Preclinical Program Updates (GlobeNewswire) +6.16%
Jan-07-22 07:05AM	Monopar to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire) +6.67%
Dec-08-21 08:00AM	Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial (GlobeNewswire)
Nov-12-21 08:00AM	Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments (GlobeNewswire)
Oct-27-21 08:05AM	Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma (GlobeNewswire) +8.34%
Sep-22-21 08:30AM	Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-16-21 08:00AM	Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma (GlobeNewswire)
Sep-13-21 08:00AM	Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe (GlobeNewswire) -7.55%

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Radhakrishnan Karthik	Chief Financial Officer	Oct 28 '24	Buy	16.25	1,550	25,188	1,550	Oct 30 04:17 PM
Cittadine Andrew	Chief Operating Officer	Jun 20 '24	Buy	0.74	20,508	15,254	186,132	Jun 21 05:16 PM
Cittadine Andrew	Chief Operating Officer	Jun 18 '24	Buy	0.86	12,000	10,320	165,624	Jun 21 05:16 PM
Cittadine Andrew	Chief Operating Officer	Jun 14 '24	Buy	0.93	12,000	11,176	141,624	Jun 17 06:08 PM
Cittadine Andrew	Chief Operating Officer	Jun 13 '24	Buy	0.91	12,000	10,920	129,624	Jun 17 06:08 PM
Cittadine Andrew	Chief Operating Officer	Jun 17 '24	Buy	0.90	12,000	10,799	153,624	Jun 17 06:08 PM
Cittadine Andrew	Chief Operating Officer	Jun 04 '24	Buy	0.78	12,000	9,360	117,624	Jun 05 06:12 PM
Cittadine Andrew	Chief Operating Officer	Jun 03 '24	Buy	0.76	12,000	9,120	105,624	Jun 05 06:12 PM
Cittadine Andrew	Chief Operating Officer	May 31 '24	Buy	0.64	12,000	7,732	93,624	May 31 04:56 PM
Cittadine Andrew	Chief Operating Officer	May 30 '24	Buy	0.64	12,000	7,676	81,624	May 31 04:56 PM
Cittadine Andrew	Chief Operating Officer	May 29 '24	Buy	0.64	12,000	7,643	69,624	May 31 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNPR

Monopar Therapeutics Inc

Upgrade your FINVIZ experience